Psychiatry

A post-hoc analysis of the STEP trials found semaglutide for weight management doesn’t increase depression or suicidal thoughts in individuals without major mental disorders.

This month in review highlights MDMA-assisted therapy coverage, experiences with zuranolone a year after its approval, and early positive data on potential treatments.

A phase 2 trial met its primary endpoint, showing NBI-1117568, the first M4 selective agonist, is effective and safe at treating adult schizophrenia.

Michigan Medicine and U-M research finds a bidirectional link between mental health disorders and chronic diabetes complications, urging comprehensive screenings.

A new study significantly demonstrated semaglutide, but not liraglutide, is associated with suicidal ideation.

A new study found unvaccinated people have a greater risk of depression or serious mental health illnesses compared to vaccinated people.

In this episode of Crisis Point, PTSD experts and a trial participant react to the FDA’s decision on MDMA-assisted therapy for PTSD.

Preliminary Phase 1b data demonstrated the favorable safety and tolerability profile of VLS-01 buccal film, with psychedelic effects resolved by 120 minutes.

Cristina Pearse, an MDMA-assisted therapy trial participant, expresses disappointment in the FDA’s decision not to approve MDMA-assisted therapy.

The US FDA has issued a CRL and requested an additional phase 3 trial for MDMA-assisted therapy in the management of PTSD.

A new study revealed an increased risk of psychiatric and autoimmune comorbidities after an alopecia areata diagnosis.

Geoffrey Grammer, MD closes this series highlighting the administration options of esketamine, its safety profile, and the importance of monitoring patients using this treatment.

Robert Zalewski-Zaragoza, MD expands on the option of esketamine for treatment resistant depression, highlighting the unique mechanism of action and application.

William Sauve, MD shares the growing landscape of treatments for treatment resistant depression (TRD) and their mechanism of action, such as brain stimulation through electroconvulsive therapy or medication such as esketamine.

Harman Deol, MD begins this series presenting an overview of treatment resistant depression (TRD), highlighting its prevalence along with its impact on patients and the healthcare system.

A study suggests TMR can boost PTSD treatment by enhancing memory consolidation during sleep, showing significant symptom reduction without affecting sleep quality.

PTSD experts explore unmet PTSD needs, the potential of psychedelic therapies, and key unanswered questions about MDMA-assisted therapy for PTSD.

A recent study found a high prevalence of head injuries among law enforcement officers may make them more prone to experiencing mental health issues.

In an interview with HCPLive, Angela Moreland, PhD, highlighted the largest takeaway from the study on the psychiatric impact of mass shootings on the greater community.

In this video series segment, Casey Paleos, MD, provides insight into what he considers to be the most pertinent unanswered questions surrounding MDMA-assisted therapy in PTSD.

In this video series segment, Casey Paleos, MD, discusses his outlook on the potential of psychedelic therapies in PTSD looking forward.

In this video series segment, Casey Paleos, MD, offers insight into the impact of historic stigma associated with psychedelic therapies on acceptance in psychiatric care.

In this video series segment, Casey Paleos, MD, describes his interpretation of clinical trial data for MDMA-assisted therapy in PTSD as well as his reaction to the FDA PDAC vote in early June.

In this video series segment, Casey Paleos, MD, provides perspective on the current options and unmet needs in the management of posttraumatic stress disorder.

In a "secret shopper" study, investigators posing as Medicaid enrollees found many clinicians in Medicaid provider directories do not accept Medicaid insurance.